About

Mr. Hurst has more than twenty-five years experience in the biopharmaceutical industry and has contributed to the success of numerous complex and challenging healthcare projects. As the Chief Business Officer for The Immune Tolerance Institute (2007-2011), he helped establish a human immune monitoring institute for The Regents of the University of California that discovers and develops immune biomarkers. As a consultant to The World Bank and BIO Ventures for Global Health (2005-2009), he helped establish an innovative funding mechanism for pneumococcal vaccines for the developing world (PneumoAMC), including capacity for two billion vaccine doses and funding of more than $4 billion over the next decade. As Founder, President & CEO of Sequential, Inc. (2002-2004), his team acquired and developed a clinical-stage oncology drug for the treatment of multi-drug resistance. While at Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.) (1994-2002), he held several senior executive positions, including Executive Vice President, General Counsel and Secretary, interim Senior Vice President of Operations, Vice President of Intellectual Property and Licensing and Head of Business Development and helped the company grow to over 700 employees, raise more than $700 million in investment capital and out-license multiple clinical development projects, generating revenues in excess of $100 million annually. Mr. Hurst is a graduate of Golden Gate University, School of Law and the University of California, Berkeley. 

Practices Areas

Intellectual Property

Language

English

Contact